SCHEMBL22454426

SCHEMBL22454426

c1ccc(N(c2ccc(-c3ccc4c(c3)sc3c5ccccc5sc43)cc2)c2ccc3sc4ccccc4c3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
ALDH1A1 P00352 4/20 0.39
RAB9A P51151 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LIMK1 P53667 2/20 0.38
GPR3 P46089 1/20 0.37
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
ALOX5 P09917 1/20 0.35
CYP1A2 P05177 1/20 0.34
PTGIR P43119 1/20 0.34
PTPN7 P35236 1/20 0.33
DUSP3 P51452 1/20 0.33
PTPN12 Q05209 1/20 0.33
PTPN22 Q9Y2R2 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22454546 0.96 MAPT (0.40) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL22454545 0.95 MAPT (0.37) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL24000287 0.95 MAPT (0.39) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL22454396 0.93 MAPT (0.40) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL31672580 0.93 MAPT (0.41) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL25889990 0.93 MAPT (0.41) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL24883289 0.93 MAPT (0.41) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL15614313 0.92 ALDH1A1 (0.41) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL15614307 0.92 ALDH1A1 (0.41) MAPTALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL15614386 0.92 ALDH1A1 (0.41) MAPTALDH1A1RAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230209999-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND MONOAMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-29 US disclosed
US-20230209999-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND MONOAMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-29 US disclosed
US-20200303653-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND MONOAMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2020-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230209999-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND MONOAMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE COMT, MAOA, MAOB MAPT 1048/4885ALDH1A1 188/4885RAB9A 3040/4885
US-20200303653-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND MONOAMINE COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE COMT, MAOA, MAOB MAPT 1048/4885ALDH1A1 188/4885RAB9A 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.